EP1945669A4 - Chimäre antikörper mit neuweltprimatenregionen - Google Patents

Chimäre antikörper mit neuweltprimatenregionen

Info

Publication number
EP1945669A4
EP1945669A4 EP06774813A EP06774813A EP1945669A4 EP 1945669 A4 EP1945669 A4 EP 1945669A4 EP 06774813 A EP06774813 A EP 06774813A EP 06774813 A EP06774813 A EP 06774813A EP 1945669 A4 EP1945669 A4 EP 1945669A4
Authority
EP
European Patent Office
Prior art keywords
regions
chimeric antibodies
new world
world primate
primate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06774813A
Other languages
English (en)
French (fr)
Other versions
EP1945669A1 (de
Inventor
Philip Anthony Jennings
Anthony Gerard Doyle
Adam William Clarke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals Australia Pty Ltd
Original Assignee
Arana Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2005904406A external-priority patent/AU2005904406A0/en
Application filed by Arana Therapeutics Ltd filed Critical Arana Therapeutics Ltd
Publication of EP1945669A1 publication Critical patent/EP1945669A1/de
Publication of EP1945669A4 publication Critical patent/EP1945669A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP06774813A 2005-08-15 2006-08-15 Chimäre antikörper mit neuweltprimatenregionen Withdrawn EP1945669A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2005904406A AU2005904406A0 (en) 2005-08-15 New World Antibodies
PCT/AU2006/001166 WO2007019621A1 (en) 2005-08-15 2006-08-15 Chimeric antibodies with new world primate regions

Publications (2)

Publication Number Publication Date
EP1945669A1 EP1945669A1 (de) 2008-07-23
EP1945669A4 true EP1945669A4 (de) 2009-07-22

Family

ID=37757238

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06774813A Withdrawn EP1945669A4 (de) 2005-08-15 2006-08-15 Chimäre antikörper mit neuweltprimatenregionen

Country Status (13)

Country Link
EP (1) EP1945669A4 (de)
JP (1) JP2009504686A (de)
KR (1) KR20080068005A (de)
CN (2) CN101287763A (de)
AU (1) AU2006281981A1 (de)
BR (2) BRPI0614430A2 (de)
CA (1) CA2619245A1 (de)
MX (1) MX2008002161A (de)
NO (1) NO20080800L (de)
NZ (1) NZ565904A (de)
RU (1) RU2008110058A (de)
WO (1) WO2007019621A1 (de)
ZA (2) ZA200802246B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS20070027A (en) 2004-07-26 2008-11-28 Biogen Idec Ma Inc., Anti-cd154 antibodies
KR20090039666A (ko) 2006-02-01 2009-04-22 아라나 테라퓨틱스 리미티드 도메인 항체 구조체
JP5721951B2 (ja) * 2007-03-22 2015-05-20 バイオジェン アイデック マサチューセッツ インコーポレイテッド 抗体、抗体誘導体、および抗体断片を含む、ｃｄ１５４に特異的に結合する結合タンパク質ならびにその使用
CA2733742A1 (en) * 2008-08-14 2010-02-18 Cephalon Australia Pty Ltd Variant domain antibodies
RU2535034C2 (ru) * 2010-08-06 2014-12-10 Олег Ильич Эпштейн Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида
RU2517085C2 (ru) * 2010-08-06 2014-05-27 Олег Ильич Эпштейн Комплексное лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида
RU2516931C2 (ru) * 2010-08-06 2014-05-20 Олег Ильич Эпштейн Способ и композиция для профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида
RU2577299C2 (ru) * 2011-07-04 2016-03-10 Олег Ильич Эпштейн Способ лечения инфекционных заболеваний и комплексное лекарственное средство для лечения инфекционных заболеваний
RU2519862C2 (ru) * 2010-08-06 2014-06-20 Олег Ильич Эпштейн Комплексное лекарственное средство и способ профилактики и лечения инфекционных вирусных заболеваний
RU2535033C2 (ru) * 2010-08-06 2014-12-10 Олег Ильич Эпштейн Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида
RU2521392C2 (ru) * 2010-08-06 2014-06-27 Олег Ильич Эпштейн Комплексное лекарственное средство для лечения вирусных заболеваний и способ лечения вирусных заболеваний
RU2505312C2 (ru) * 2010-08-06 2014-01-27 Олег Ильич Эпштейн Комплексное лекарственное средство для лечения гриппа различных типов
RU2502521C2 (ru) * 2010-08-06 2013-12-27 Олег Ильич Эпштейн Комплексное лекарственное средство для лечения бактериальных инфекций и способ лечения бактериальных инфекций
RU2579262C1 (ru) * 2014-10-02 2016-04-10 Мапикс Эс.Эй.Ар.Эл. Лекарственное средство для лечения инфекционных заболеваний
CL2015002152A1 (es) * 2015-07-31 2016-06-03 Pontificia Universidad Católica De Chile Anticuerpos monoclonales específicos para el antígeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnostico de la infección causada por vrsh

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993002108A1 (en) * 1991-07-25 1993-02-04 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
WO2002033042A2 (en) * 2000-10-17 2002-04-25 The Regents Of The University Of California Recombinant antibody fragments as autoantibody antagonists
US20030143682A1 (en) * 2000-11-07 2003-07-31 Nicolaides Nicholas C. Antibodies and methods for generating genetically altered antibodies with high affinity
WO2004003019A2 (en) * 2002-06-28 2004-01-08 Domantis Limited Immunoglobin single variant antigen-binding domains and dual-specific constructs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004290016A1 (en) * 2003-11-07 2005-05-26 Amgen Inc. Monkey immunoglobulin sequences

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993002108A1 (en) * 1991-07-25 1993-02-04 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
WO2002033042A2 (en) * 2000-10-17 2002-04-25 The Regents Of The University Of California Recombinant antibody fragments as autoantibody antagonists
US20030143682A1 (en) * 2000-11-07 2003-07-31 Nicolaides Nicholas C. Antibodies and methods for generating genetically altered antibodies with high affinity
WO2004003019A2 (en) * 2002-06-28 2004-01-08 Domantis Limited Immunoglobin single variant antigen-binding domains and dual-specific constructs

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FOOTE J ET AL: "Antibody framework residues affecting the conformation of the hypervariable loops", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 224, no. 2, 20 March 1992 (1992-03-20), pages 487 - 499, XP024011188, ISSN: 0022-2836, [retrieved on 19920320] *
HOLT L J ET AL: "Domain antibodies: proteins for therapy", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 21, no. 11, 1 November 2003 (2003-11-01), pages 484 - 490, XP004467495, ISSN: 0167-7799 *
REITER Y ET AL: "An antibody single-domain phage display library of a native heavy chain variable region: isolation of functional single-domain VH molecules with a unique interface", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 290, no. 3, 1 January 1999 (1999-01-01), pages 685 - 698, XP004461990, ISSN: 0022-2836 *
See also references of WO2007019621A1 *
SPEIDEL M T ET AL: "Detection of human and marmoset immunoglobulin heavy chain by a polyclonal antiserum to a marmoset immunoglobulin-related T cell product", EXPERIMENTAL AND CLINICAL IMMUNOGENETICS, S.KARGER, BASEL, CH, vol. 6, no. 4, 1 January 1989 (1989-01-01), pages 245 - 250, XP009116561, ISSN: 0254-9670 *
VON BUDINGEN HANS-CHRISTIAN ET AL: "Characterization of the expressed immunoglobulin IGHV repertoire in the New World marmoset Callithrix jacchus", IMMUNOGENETICS, vol. 53, no. 7, September 2001 (2001-09-01), pages 557 - 563, XP002527012, ISSN: 0093-7711 *

Also Published As

Publication number Publication date
CA2619245A1 (en) 2007-02-22
ZA200802246B (en) 2009-09-30
ZA200802247B (en) 2009-08-26
NZ565904A (en) 2012-02-24
CN101287763A (zh) 2008-10-15
BRPI0614430A2 (pt) 2011-03-29
JP2009504686A (ja) 2009-02-05
WO2007019621A1 (en) 2007-02-22
CN101287762A (zh) 2008-10-15
MX2008002161A (es) 2008-04-22
RU2008110058A (ru) 2009-09-27
AU2006281981A1 (en) 2007-02-22
BRPI0614867A2 (pt) 2012-01-31
KR20080068005A (ko) 2008-07-22
NO20080800L (no) 2008-05-09
EP1945669A1 (de) 2008-07-23

Similar Documents

Publication Publication Date Title
ZA200802247B (en) Chimeric antibodies with new world primate regions
EP1945668A4 (de) Synthetische antikörper mit framework-regionen von neuweltprimaten
EP1969009A4 (de) Chimäre antikörper mit anteilen von bindungsregionen neuer-welt-primaten
HK1218126A1 (zh) 抗體
PT1874927E (pt) Celulases melhoradas
IL187106A (en) Sclerostin binds antibody
IL190472A0 (en) Anti-glypican-3 antibody
AP2007004243A0 (en) Antibodies to myostatin
EP1854410A4 (de) Biosensor mit angekoppelter nadel
IL185366A0 (en) Antibody
GB0517487D0 (en) Antibodies
EP1896047A4 (de) Antikörper gegen gfr-alpha-3
GB0505489D0 (en) Antibodies
GB0512278D0 (en) Antibodies
GB0505054D0 (en) Antibodies
GB0519883D0 (en) Antibodies
GB0509392D0 (en) Improvements to the controllable petrol can
GB0616587D0 (en) Intelligent buggy
GB0521710D0 (en) Fork extension
GB0607376D0 (en) Antibodies
GB0606276D0 (en) Antibodies
GB0503580D0 (en) Travel phone
GB0500400D0 (en) Antibody
GB0501709D0 (en) H/h/t
GB0510408D0 (en) Harware interface

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080317

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/46 20060101ALI20090528BHEP

Ipc: A61K 39/395 20060101ALI20090528BHEP

Ipc: C07K 16/18 20060101AFI20070420BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20090618

17Q First examination report despatched

Effective date: 20091006

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CEPHALON AUSTRALIA PTY LTD

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130301